1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order placing FDA-approved marijuana products and marijuana products subject to a qualifying state-issued medical license in Schedule…
Marijuana’s proposed move from Schedule I to Schedule III under the Controlled Substances Act has renewed focus on what rescheduling could mean for marijuana-related businesses (MRBs) and the financial institutions that serve…
Schedule I → Schedule III: A Landmark Policy Shift with Important Limits
2026 brings cautious, steady progress in a continually evolving regulatory and commercial landscape. Stakeholders should expect ongoing change across policy, markets, compliance, and enforcement, creating both risks and…
On December 18, 2025, President Donald Trump signed an Executive Order titled Increasing Medical Marijuana and Cannabidiol Research, marking the most consequential federal cannabis policy action in decades.
Are you not entertained? In a much-anticipated ceremony in the Oval Office, President Trump signed an executive order that (1) directs the attorney general to expeditiously reschedule marijuana to Schedule III and (2) instructs…
Federal Laws Implicated by the Commercial Insuring of Marijuana
Holland & Knight The cannabis industry in the United States has experienced rapid growth, with an increasing number of states legalizing the use of marijuana for medical and recreational purposes. S. S. population live in states…
Author: Vince Sliwoski Congressman Earl Blumenauer (D-Oregon) is retiring next month. Mr. Blumenauer, or “Earl” as he often asked to be called, has been a leading proponent of cannabis reform since 1973, when Oregon was the first…
Author: Vince Sliwoski Congressman Earl Blumenauer (D-Oregon) is retiring next month. Mr. Blumenauer, or “Earl” as he often asked to be called, has been a leading proponent of cannabis reform since 1973, when Oregon was the first…
McGlinchey Stafford SOURCE JD SUPRA The U.S. Drug Enforcement Agency’s proposal to reschedule cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA) has generated considerable buzz across…
Source: JD Supra https://www.jdsupra.com/legalnews/does-rescheduling-cannabis-make-it-7300251/
S. Drug Enforcement Administration (“DEA”) is recommending reclassifying cannabis from Schedule I to Schedule III. S. Department of Health and Human Services (“HHS”) and President Biden’s directive, acknowledges cannabis’ medical…
The Department of Justice’s move to reclassify marijuana as a less dangerous drug, on which it began formal proceedings on May 16, won’t legalize state-level adult…
Title: Bond-Funded State Cannabis Loan Underwriting Can Increase Competition While Reversing Race Bias Author: Benjamin C. Varadi, Assistant Professor, Vermont Law & Graduate School. Biography & Acknowledgments:
S. Drug Enforcement Administration (DEA) released the proposed rule (Proposed Rule) to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Only one day after reports surfaced that the Drug Enforcement Administration (DEA) will proceed with rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), Senators Charles Schumer (D-NY),…
On April 30, 2024, the Associated Press (AP) reported the Drug Enforcement Administration (DEA) will propose a rule to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Jedediah Ande, Guillermo Artiles, Kelly Brennan, Gianni Garyfallos, Ryan Magee, William Palatucci
“Cannabis is currently a Schedule 1 drug which includes drugs like heroin and LSD. The Biden administration is moving it to Schedule 3 which includes things like Tylenol with Codeine and steroids,” explains Stanton.